+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

European Graves' disease Market 2019-2025

  • PDF Icon

    Report

  • February 2020
  • Region: Europe
  • Orion Market Research Private Limited
  • ID: 5116623
UP TO OFF until Dec 31st 2022
European Graves’ disease Market Size, Share & Trends Analysis Report by Diagnosis (Ultrasound, Imaging Tests, Radioactive Iodine Uptake, and Blood Sample), by Treatment (Anti- Thyroid Medication, Radioactive Iodine Therapy, and Surgery) Forecast Period 2019-2025.

European Graves’ disease market is growing at a CAGR of around 4.4% during the forecast period. Europe consists of numerous key economies including the UK, Germany, Spain, Italy, and Russia among various others which play a significant role in the development of the Grave’s market in the region. The key reason which is promoting the growth of the market in Europe is the changing lifestyle and higher prevalence of smoking in the countries of European region is expected to promote the prevalence of Grave’s disease, thereby creating opportunity for the growth of the European Graves’ diseases market over the forecast period.

Europe is the well-established region comprises of few of the largest economies of the world. The region has established healthcare industry due to growing funding in the healthcare R&D and awareness programs. This directly impacts the funding and awareness about thyroid related diseases such as Grave’s disease, thyroid cancer and others. Presence of the key market players such as Apitope technology Ltd., GlaxoSmithKline PLC and others is also affecting the growth of the market. Growing prevalence of type-1 diabetes is one of the major factors contributing significantly in the European Grave’s disease market.

Further, Apitope International NV is a biotechnology company, based in Belgium, that manufactures and markets commercialized products for autoimmune disease. The company provides product candidate ATX-GD-59 that is a disease-modifying treatment for Grave’s disease. ATX-GD-59 is presently being assessed in a Phase I study in patients and the company plans to initiate a Phase II study in the first quarter of 2019. Thus, the presence of the market players strengthens the domestic presence and also aids in the growth of the European Graves’ disease market.

Research Methodology:

The market study of the European Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. European Graves’ Disease Market Research and Analysis by Diagnosis
2. European Graves’ Disease Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive Research Methodology of the European Graves’ disease market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European Graves’ disease market.
  • Insights about market determinants which are stimulating the European Graves’ disease market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Allergan PLC
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co. Inc
  • Mylan NV
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.